XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1Close
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 3,026 $ 3,194
Accounts receivable, net of allowances of $121 in 2024 and $129 in 2023 2,521 2,690
Inventories 2,988 2,824
Prepaid expenses and other current assets 865 892
Total current assets 9,400 9,600
Property, plant and equipment, net 4,370 4,433
Goodwill 6,430 6,514
Other intangible assets, net 5,905 6,079
Operating lease right-of-use assets 531 524
Other non-current assets 1,152 1,126
Total assets 27,788 28,276 Close
Current liabilities:    
Current maturities of long-term debt and finance lease obligations 2,634 2,668
Accounts payable 1,329 1,241
Accrued expenses and other current liabilities 2,402 2,594
Total current liabilities 6,365 6,503
Long-term debt and finance lease obligations, less current portion 11,092 11,130
Operating lease liabilities 444 438
Other non-current liabilities 1,652 1,737
Total liabilities 19,553 19,808 Close
Commitments and contingencies
Equity:    
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2024 and 2023 683 683
Common stock in treasury, at cost, 173,930,493 shares in 2024 and 175,861,893 shares in 2023 (11,130) (11,230)
Additional contributed capital 6,339 6,389
Retained earnings 16,003 16,114
Accumulated other comprehensive loss (3,722) (3,554)
Total Baxter stockholders’ equity 8,173 8,402
Noncontrolling interests 62 66
Total equity 8,235 8,468 Close
Total liabilities and equity $ 27,788 $ 28,276